Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exarafenib - Pierre Fabre

Next Previous
X
Search
Drug Profile

Exarafenib - Pierre Fabre

Alternative Names: BRAF kinase inhibitor - Kinnate Biopharma; KIN-002787; KIN-2787; RAF inhibitor - Kinnate Biopharma

Latest Information Update: 28 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kinnate Biopharma
  • Developer Kinnate Biopharma; Kinnjiu Biopharma
  • Class Amides; Antineoplastics; Benzene derivatives; Fluorinated hydrocarbons; Morpholines; Propanolamines; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Proto-oncogene protein b-raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Malignant melanoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Late-stage disease, Metastatic disease) in China (PO)
  • 28 Sep 2024 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Late-stage disease, Metastatic disease) in South Korea (PO)
  • 28 Sep 2024 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Late-stage disease, Metastatic disease) in Taiwan (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top